Aero

AeroRx Therapeutics is a clinical-stage biopharmaceutical company focused on developing best-in-class nebulized combination therapies for chronic respiratory diseases, specifically chronic obstructive pulmonary disease (COPD). The company's lead program, AERO-007, is a nebulized fixed-dose combination of a long-acting beta-2 adrenergic receptor agonist (LABA) and a long-acting muscarinic receptor antagonist (LAMA) designed for patients who are poorly served by traditional handheld inhalers. AeroRx is also advancing AERO-111, a triple combination therapy (LABA/LAMA/ICS) for patients requiring anti-inflammatory treatment. By utilizing nebulized delivery, the company aims to improve dosing consistency and adherence in high-risk COPD populations. Headquartered in La Jolla, California, AeroRx is led by a team with extensive experience in aerosol drug delivery and respiratory clinical development.